PCI 32765 |
PCI-32765 |
CRA-032765 |
PCI-32765-00 |
IMBRUVICA |
IBRUTINIB |
PC-32765 |
IMBRUVICA® |
1-[(3R)-3-[4-AMINO-3-(4-PHENOXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDIN-1-YL]PROP-2-EN-1-ONE |
PCI32765 |
chembl:CHEMBL1873475 |
rxcui:1442981 |
chemidplus:936563-96-1 |
drugbank:09053 |
pubchem.compound:24821094 |
FDA Approval | not approved |
Drug Class | small molecule |
Drug Indications | antineoplastic agent |
FDA Approval | Mantle cell lymphoma, Chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia |
Drug Class | Kinase Inhibitors |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 cyp3a5 substrates |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | kinase inhibitor |
Drug Categories | narrow therapeutic index drugs |
Drug Categories | tyrosine kinase inhibitors |
inhibitor (inhibitory) |
Drug family | BTK inhibitor |
Alteration | BTK:C481S |
Alteration | BTK:C481. |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Direct Interaction? | False |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Direct Interaction? | False |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
IBRUTINIB | DrugBank Drug Name |
936563-96-1 | CAS Number |
Imbruvica | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Categories | antineoplastic agents |
PCI-32765 | Development Name |
IBRUTINIB | Generic Name |
IMBRUVICA | Trade Name |
Drug Class | Kinase Inhibitors |
FDA Approval | Mantle cell lymphoma, Chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia |
Drug Indications | antineoplastic agent |
Drug Class | small molecule |
FDA Approval | not approved |
CHEMBL1873475 | ChEMBL Drug ID |
D04SHG | TTD Drug ID |
D09KTS | TTD Drug ID |
IBRUTINIB | GuideToPharmacology Ligand Name |